GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » Beneish M-Score

Immuron (STU:ANWA) Beneish M-Score : -2.01 (As of May. 17, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Immuron Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.01 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Immuron's Beneish M-Score or its related term are showing as below:

STU:ANWA' s Beneish M-Score Range Over the Past 10 Years
Min: -787.36   Med: -2.38   Max: 6.58
Current: -2.01

During the past 9 years, the highest Beneish M-Score of Immuron was 6.58. The lowest was -787.36. And the median was -2.38.


Immuron Beneish M-Score Historical Data

The historical data trend for Immuron's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Beneish M-Score Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -4.50 -2.75 6.58 0.88 -2.01

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.88 - -2.01 -

Competitive Comparison of Immuron's Beneish M-Score

For the Biotechnology subindustry, Immuron's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuron's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Immuron's Beneish M-Score falls into.



Immuron Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Immuron for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.2664+0.528 * 0.9425+0.404 * 1.629+0.892 * 2.1965+0.115 * 0.827
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5539+4.679 * -0.032009-0.327 * 1.5972
=-2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was €0.26 Mil.
Revenue was €1.12 Mil.
Gross Profit was €0.81 Mil.
Total Current Assets was €12.64 Mil.
Total Assets was €13.62 Mil.
Property, Plant and Equipment(Net PPE) was €0.12 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.03 Mil.
Selling, General, & Admin. Expense(SGA) was €3.15 Mil.
Total Current Liabilities was €1.38 Mil.
Long-Term Debt & Capital Lease Obligation was €0.09 Mil.
Net Income was €-2.35 Mil.
Gross Profit was €-0.30 Mil.
Cash Flow from Operations was €-1.61 Mil.
Total Receivables was €0.44 Mil.
Revenue was €0.51 Mil.
Gross Profit was €0.35 Mil.
Total Current Assets was €15.74 Mil.
Total Assets was €16.52 Mil.
Property, Plant and Equipment(Net PPE) was €0.15 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.03 Mil.
Selling, General, & Admin. Expense(SGA) was €2.59 Mil.
Total Current Liabilities was €1.00 Mil.
Long-Term Debt & Capital Lease Obligation was €0.12 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.258 / 1.118) / (0.441 / 0.509)
=0.230769 / 0.866405
=0.2664

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.348 / 0.509) / (0.811 / 1.118)
=0.683694 / 0.725403
=0.9425

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (12.643 + 0.124) / 13.621) / (1 - (15.737 + 0.151) / 16.524)
=0.062697 / 0.038489
=1.629

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.118 / 0.509
=2.1965

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.029 / (0.029 + 0.151)) / (0.03 / (0.03 + 0.124))
=0.161111 / 0.194805
=0.827

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3.146 / 1.118) / (2.586 / 0.509)
=2.813953 / 5.08055
=0.5539

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.093 + 1.375) / 13.621) / ((0.116 + 0.999) / 16.524)
=0.107775 / 0.067478
=1.5972

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-2.346 - -0.302 - -1.608) / 13.621
=-0.032009

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Immuron has a M-score of -2.15 suggests that the company is unlikely to be a manipulator.


Immuron Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Immuron's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron (STU:ANWA) Business Description

Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (STU:ANWA) Headlines

No Headlines